Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register - Dixon, W G; Watson, K; Lunt, M (Arthritis Rheum, 2006)
et al.